Meeting
2022 ASCO Annual Meeting
Camrelizumab in combination with concurrent chemoradiotherapy as first-line treatment for nonoperative head and neck cancer: A comparative study.
Authors
Feng Liu
Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
Feng Liu , Wenxiao Huang , Hui Wang , Cuihong Jiang , Hailin Zhang , Xiangwei Wu , Haolei Tan , Jinyun Li , Pingqing Tan , Lili He , Shuai Xiao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6063)
DOI
10.1200/JCO.2022.40.16_suppl.6063
Abstract #
6063
Poster Bd #
55
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
First Author: Chunmei Bai
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Camrelizumab plus apatinib for immunochemotherapy-treated advanced esophageal squamous cell carcinoma: Preliminary results of cohort 2 in CAP 02 study.
First Author: Feng Wang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes of patients with advanced gastric cancer treated with FOLFIRI.
First Author: Ali Fawaz
